1
Return

LGALS1 promotes the malignant progression and sunitinib resistance of clear cell renal cell carcinoma by reprogramming fatty acid metabolism

delete2026-06-20
delete0
PRE
AI
S
Sichen Di
T
Tong Wu
J
Ji Liu
S
Shuai Liu
K
Keqiang Li
W
Wei Yang
W
Wenjin Chen
Q
Qiwei Yang *
G
Guangchun Wang *
X
Xudong Yao *
H
Haimin Zhang *
DOI：10.1016/j.intimp.2026.117038delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
• LGALS1 is significantly upregulated in ccRCC, correlates with advanced stage, metastasis, and poor prognosis, and serves as an independent prognostic factor. • LGALS1 enhances ccRCC cell proliferation, migration, invasion, and lipid accumulation, driving sunitinib resistance in vitro. • LGALS1 activates the p38/ERK pathway to suppress PPARα/CPT1A, inhibiting fatty acid oxidation and promoting lipid metabolic reprogramming. • Inhibiting LGALS1 with OTX008 reverses sunitinib resistance, suppresses Subcutaneous tumor growth and lung metastasis in vivo.

Journal

International Immunopharmacology cover
International Immunopharmacology
IF:
4.7
Papers:
1.6W
Citations:
4.1W

Organization

S
shanghai jiao tong university
Scholars:
15.1W
Papers: 11.5W
Citations: 159
T
tongji university
Scholars:
7.5W
Papers: 5.8W
Citations: 98
Cited Papers

Cited Papers

Citing Papers

Citing Papers